Article de revue
Indian vaccine innovation: the case of Shantha Biotechnics
The Shantha case study underscores the important role the private sector can play in global health and access to medicines. Home-grown companies in the developing world are becoming a source of low-cost, locally relevant healthcare R&D for therapeutics such as vaccines. Such companies may be compelled by market forces to focus on products relevant to diseases endemic in their country. Sanofi-Aventis\' acquisition of Shantha reveals that even large pharmaceutical companies based in the developed world have recognized the importance of meeting the health needs of the developing world. Collectively, these processes suggest an ability to tap into private sector investments for global health innovation, and illustrate the globalization of healthcare R&D to the developing world.
Langues
- Anglais
Journal
Global Health
Volume
9
Type
Article de revue
Catégories
- Vaccins et dispositifs d'administration
Pays
- Inde
